Completed PHASE4 INTERVENTIONAL 2-arm NCT06228092

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

A Blinded Randomized Study of Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients (≥ 75 Years)

Sponsor: Matias Vested

Conditions Neuromuscular Blockade, Residual

Interventions Sugammadex neostigmine/glycopyrrolate

Updated 4 times since 2024 Last updated: Aug 19, 2025 Started: Dec 4, 2023 Primary completion: May 4, 2025 Completion: May 4, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06228092, this PHASE4 trial focuses on Neuromuscular Blockade, Residual and remains completed. Sponsored by Matias Vested, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4

Status: Recruiting → Completed
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Matias Vested

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark